Elsevier

Annals of Oncology

Volume 27, Supplement 3, September 2016, Pages iii25-iii34
Annals of Oncology

review
ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology

https://doi.org/10.1093/annonc/mdw303Get rights and content
Under an Elsevier user license
open archive

ABSTRACT

The Network Genomic Medicine (NGM) has established the first paradigm model for central molecular testing and clinical trial platforms enabling the delivery of decentralised therapies in a patient-oriented setting. Here we describe the structures of the network and give a summary of technologies to identify patients with anaplastic lymphoma kinase (ALK) fusion positive lung adenocarcinomas.

Comprehensive molecular genotyping of lung cancers has become a key requirement for guiding therapeutic decisions. As a paradigm model of implementing next-generation comprehensive diagnostics, Network Genomic Medicine (NGM) has established central diagnostic and clinical trial platforms for centralised testing and decentralised personalised treatment in clinical practice. Here, we describe the structures of the NGM network and give a summary of technologies to identify patients with anaplastic lymphoma kinase (ALK) fusion-positive lung adenocarcinomas. As unifying test platforms will become increasingly important for delivering reliable, quick and affordable tests, the NGM diagnostic platform is currently implementing a comprehensive hybrid capture-based parallel sequencing pan-cancer assay.

Key words

network genomic medicine
anaplastic lymphoma kinase
fluorescence in situ hybridisation
immunohistochemistry
parallel sequencing
hybrid capture-based parallel sequencing

Cited by (0)